Eye drop safety study for people getting anti-VEGF injections
Part of Eyes & vision clinical trials.
This study tests a new eye drop or solution (IRX-101) to see if it is safe and tolerable when given before or after your regular eye injections for conditions like wet macular degeneration. The goal is to find a way to make these injections more comfortable or safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be getting anti-VEGF eye injections (like Eylea, Lucentis, or Avastin) in one or both eyes.
- You should not have a current or past eye infection (endophthalmitis) or current eye inflammation (uveitis).
- You must not have very poor vision in one eye while receiving injections only in the better-seeing eye.
- You cannot be using viscous numbing gel, getting steroid eye injections, or participating in another trial.
- If you are able to become pregnant, you must not be pregnant, planning to become pregnant, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
This study tests an experimental eye drop medication in healthy adults to see if it is safe and how the body handles it. It may help develop a new treatment for eye conditions.
This trial tests a new eye drop called NT-101 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if the drops can improve vision and reduce fluid in the eye, possibly as a less invasive alternative to injections.
This phase 1 trial tests the safety of an investigational eye drop called IVMED-85 in healthy adults aged 18-49. Participants will receive the eye drops and be monitored for any side effects over 6 weeks.
This trial tests a new eye injection (GenSci148) for people with wet age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. The injection may help reduce swelling and abnormal blood vessel growth in the retina, which can improve or stabilise vision.
Hear when a new Retinal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.